Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. COR
COR logo

COR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cencora Inc (COR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
352.190
1 Day change
-2.66%
52 Week Range
377.540
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Cencora Inc (COR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite the recent price decline, the company's strong financial performance, positive analyst sentiment, and hedge fund buying activity indicate long-term growth potential.

Technical Analysis

The stock's MACD is negative and expanding, indicating bearish momentum in the short term. RSI is neutral at 35.268, showing no clear overbought or oversold condition. However, the moving averages (SMA_5 > SMA_20 > SMA_200) are bullish, suggesting an overall upward trend in the long term. The stock is near its support level at $355.08, which could provide a good entry point.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low put-call ratios indicate bullish sentiment in the options market, with more interest in calls than puts.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
7

Positive Catalysts

  • Hedge funds are significantly increasing their positions, with a 2472.49% rise in buying activity.

  • Analysts have consistently raised price targets, with the latest targets ranging from $400 to $440, reflecting strong confidence in the company's growth.

  • The company has cleared risks related to Walgreens and government drug pricing, opening up multi-year growth opportunities.

  • Strong Q1 2026 financial performance, with revenue, net income, EPS, and gross margin all showing significant YoY growth.

Neutral/Negative Catalysts

  • The stock has experienced a recent price decline of -2.42% in the regular market and -0.54% in pre-market trading, which could indicate short-term bearish sentiment.

  • The MACD indicator is showing bearish momentum.

Financial Performance

In Q1 2026, Cencora reported a 5.45% YoY increase in revenue to $85.93 billion, a 14.54% YoY increase in net income to $559.65 million, and a 14.80% YoY increase in EPS to $2.87. Gross margin also improved by 17.63% YoY to 3.27%, indicating strong operational efficiency and profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are overwhelmingly positive on Cencora, with multiple upgrades and raised price targets. Recent ratings include Overweight and Buy, with price targets ranging from $400 to $440. Analysts highlight the company's leadership in specialty distribution, strategic acquisitions, and cleared risks as key drivers of growth.

Wall Street analysts forecast COR stock price to rise
9 Analyst Rating
Wall Street analysts forecast COR stock price to rise
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 361.800
sliders
Low
400
Averages
415.38
High
440
Current: 361.800
sliders
Low
400
Averages
415.38
High
440
BofA
Allen Lutz
Neutral
maintain
$360 -> $380
AI Analysis
2026-03-06
New
Reason
BofA
Allen Lutz
Price Target
$360 -> $380
AI Analysis
2026-03-06
New
maintain
Neutral
Reason
BofA analyst Allen Lutz raised the firm's price target on Cencora (COR) to $380 from $360 and keeps a Neutral rating on the shares. McKesson (MCK) "quietly" received a new National Drug Code for a biosimilar version of Neulasta a few weeks ago and while investors may be skeptical of McKesson's ambitions here, the firm frames "why this initial investor reaction could be wrong" based on seven large biosimilars coming to market over the next few years, including four that are directly addressable. The firm raised its McKesson target to reflect optionality on co-manufacturing and raised its Cencora (COR) target as well to reflect similar optionality.
Barclays
NULL -> Overweight
maintain
$400 -> $425
2026-02-13
Reason
Barclays
Price Target
$400 -> $425
2026-02-13
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Cencora to $425 from $400 and keeps an Overweight rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for COR
Unlock Now

People Also Watch